Massive previous clinical and experimental evidences demonstrated that FGFR2 is an unfavorable prognostic biomarker and antibodies targeting FGFR2 can suppress gastric cancer progression in vivo and in vitro [6–10]. This evidence concerns the gene FGFR2 and gastric cancer.